

INVESTMENT HIGHLIGHTS

- Market leader in electronic laboratory notebook software, decision-support software, cheminformatics, and chemical sourcing databases.
- Organic growth and strategic acquisitions to expand top-line, customer base and cross-selling opportunities.
- Customers include the top 35 pharmaceutical companies.
- Key customers include Eli Lilly, Johnson & Johnson, Pfizer, Schering-Plough, Merck, Bristol-Myers Squibb, Boehringer Ingelheim, ExxonMobil, and Dow Chemical.
- Announced on March 2, 2010 the divestiture of the company's HPR business unit, consisting primarily of automation tools, transitioning to more profitable software-only business.
- Cash flow positive with \$2.36 cash per share (\$82 million) at December 31, 2009 and no debt.

PRODUCTS & SERVICES


- Symyx Software powers laboratories with information that generates insight, enhances collaboration and drives productivity. Products include:
 - ♦ Symyx Notebook - an enterprise Electronic Lab Notebook (ELN) offering customizable workflows and IP protection for scientists in chemistry (analytical, synthetic, process and formulations) and biology.
 - ♦ ISIS/Isentris platform – enterprise data access, integration and analysis.
 - ♦ Lab Execution & Analysis suite – enables scientists to control, monitor and manage the acquisition of large amounts of data from automated laboratory instruments and manual instrumentation.
 - ♦ Chemistry databases – comprehensive collection of bioactivity, chemical sourcing, molecular properties, synthetic methodology, metabolism and toxicology data.

FINANCIAL HIGHLIGHTS


5-YEAR ANNUAL TOTAL REVENUES (\$ in Thousands)



2009 SOFTWARE REVENUE BY SEGMENT (\$ in Millions)




2009 REVENUE BY BUSINESS AREA (\$ in Thousands)



INVESTOR FACT SHEET

QUARTERLY REVENUE AND NON-GAAP NET INCOME (\$ in Thousands)



MARKET HIGHLIGHTS

Symyx's customers in the life sciences, chemical, energy and consumer and industrial products industries are facing increasing competition, escalating research and materials costs, and dynamic product cycles causing time-to-market constraints. As a result, R&D organizations have product development and cost goals that often cannot be met using existing in-house expertise or resources.

BUSINESS OVERVIEW

Symyx Technologies helps R&D-based companies in life sciences, chemicals, energy, and consumer and industrial products achieve breakthroughs in innovation, productivity, and return on investment. Symyx software and scientific databases power laboratories with the information that generates insight, enhances collaboration and drives productivity. Products include a market-leading electronic laboratory notebook, decision support software, and chemical informatics and sourcing databases.

Symyx was incorporated in California in 1994 and re-incorporated in Delaware in 1999.

GROWTH STRATEGY

In early 2010, Symyx is completing its transition from a research-centric business to a software business well-positioned to exploit the emerging electronic laboratory notebook market. The company's goals are to achieve the clear #1 position in ELN, to grow organically and through select acquisitions, and to consistently increase profitability to reach 20% adjusted EBITDA in 2011.

STOCK INFORMATION

Market: Nasdaq Global Select Market

Ticker symbol: SMMX

Initial public offering: November 18, 1999

Shares sold: 5.54 million at \$14.00 per share

Diluted shares outstanding: 34.7 million at 12/31/09

ANALYST COVERAGE

First Analysis

CORPORATE INFORMATION

Transfer Agent: Wells Fargo Bank Minnesota, N.A.

Legal Counsel: Cooley Godward

Independent Auditors: Ernst & Young LLP

Investor Relations: (408) 773-4075; ir@symyx.com

This fact sheet is intended to provide background information on Symyx Technologies, Inc., and it may contain forward-looking statements regarding future events or the future performance of Symyx Software within the meaning of applicable securities laws under Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Symyx's actual results could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties. These and other risk factors are discussed under "Risk Factors" in Symyx's periodic filings with the Securities and Exchange Commission (SEC). This document should be read in conjunction with the company's news releases and filings with the SEC, which are available from Symyx investor relations and accessible on the corporate website at <http://investor.symyx.com/> as well as the SEC website at www.sec.gov. Symyx expressly disclaims any obligation or undertaking to release publicly any updates or revisions to these forward-looking statements, except as the law may require.

CORPORATE HEADQUARTERS:

Symyx Technologies, Inc.
1263 East Arques Avenue
Sunnyvale, CA 94085

MAILING ADDRESS:

Symyx Technologies, Inc.
3100 Central Expressway
Santa Clara, CA 95051

(408) 773-4075

<http://investor.symyx.com/>

www.symyx.com

